Alnylam Pharmaceuticals Surges to Top Trading Volume with $390 Million Day

On May 1, 2025, Alnylam Pharmaceuticals (ALNY) experienced a significant trading day, with a total trading volume of $390 million, marking a 57.54% increase from the previous day. The stock closed at $255.13, down 3.08% from its previous close.

Alnylam Pharmaceuticals reported strong financial performance for the first quarter of 2025, with total product revenues growing by 28% year-over-year, reaching $469 million. This growth was driven by a 4% sequential improvement from the previous quarter.

In addition to its revenue growth, Alnylam also reported earnings and revenue surprises of 98.21% and 1.02%, respectively, for the quarter ended March 2025. The company's adjusted loss narrowed, reflecting improved financial health.

Royal Bank of Canada upgraded its target price for Alnylam Pharmaceuticals from $310.00 to $330.00, maintaining an "outperform" rating. This positive outlook from a major financial institution further bolstered investor confidence in the company's prospects.